How AI is reshaping clinical trials

Human oversight remains crucial as the technology is leveraged in safety monitoring, boosting clinical trial diversity and more.

By Kelly Bilodeau • March 23, 2026

Lilly’s manufacturing bet; hints of a biotech revival

Lilly is investing billions more into Chinese manufacturing — and other topics on our radar this week.

By PharmaVoice Staff • March 20, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Novartis acquisition spin-off pioneers RNA therapeutics for the heart

The newly launched Atrium Therapeutics will focus on precision RNA therapeutics for rare, genetic cardiomyopathies.

By Alexandra Pecci • March 19, 2026

As Chinese biotechs recognize their value, the bargain era may be over

Rising average upfront payments signal that buyers see value in Chinese assets.

By Kelly Bilodeau • March 18, 2026

VC sees early signs of a biotech market spring as long winter fades

The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.

By Michael Gibney • March 17, 2026

Keytruda’s reign continues; pharma’s megadeal drought

Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our radar this week.

By PharmaVoice Staff • March 13, 2026

Servier’s $2.5B cancer bet underlines a quick oncology growth strategy

Relatively new to the oncology scene, Servier has built a reputation as a serial acquirer of targeted cancer outfits as it pumps up its pipeline.

By Michael Gibney • March 10, 2026

Executives want in, but researchers want out — how pharma’s US job picture is changing

While academics are eyeing friendlier work opportunities abroad, America’s manufacturing boom is drawing industry leaders to its shores.

By Alexandra Pecci • March 10, 2026

The first KRAS drugs have been sluggish on the market. Will the next generation fare better?

The regulatory success of KRAS-targeting therapies marked a watershed moment, but there is room for improvement in the real world.

By Kelly Bilodeau • March 9, 2026

Biopharma’s recent string of CEO splits

Leaders at Bavarian Nordic, Sarepta and Alkermes recently announced plans to step down.

By Meagan Parrish • March 6, 2026

What 3 recent FDA rejections reveal about shifts inside the agency

The FDA’s approval strategy has been difficult to pin down, but recent decisions provide clues for how some of the most volatile initiatives will play out.

By Alexandra Pecci • March 4, 2026

Big Pharma’s next entrant could come from China

Companies with a growing international presence like Jiangsu Hengrui Pharmaceuticals are on their way to joining the big leagues.

By Kelly Bilodeau • March 2, 2026

Biohaven says FDA roadblocks leave rare disease patients in limbo

An FDA rejection last year for a rare disease drug from Biohaven reflects the amount of work left to get patients the treatments they need, the company says.

By Michael Gibney • Feb. 26, 2026

China’s biopharma advance draws financial investment

Experts are still keeping a close eye on geopolitical uncertainties, but licensing deals are turning into monetary growth.

By Kelly Bilodeau • Feb. 25, 2026

Will the FDA yank mRNA vaccines?

Adding increased obstacles and sowing safety doubts may be enough to chill mRNA vaccine use and development.

By Alexandra Pecci • Feb. 24, 2026

How does the FDA really feel about psychedelics? We could soon find out.

Compass Pathways’ psilocybin-based drug is edging closer to an approval but faces mixed signals from officials.

By Kelly Bilodeau • Feb. 23, 2026

Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.

Moderna’s clash with U.S. health agencies over its flu shot reflects a difficult time for vaccinemakers, but many are still playing the waiting game.

By Michael Gibney • Feb. 19, 2026

Pharma could be on the cusp of finally breaking the blood-brain barrier

Denali’s brain shuttle technology is poised for a potential landmark approval in April, and other options are gaining ground. 

By Kelly Bilodeau • Feb. 18, 2026

More drugmakers are turning to cancer combos. Will it help patients live longer?

Researchers are increasingly trying multi-pronged approaches to stop tumors in their tracks, leaving monotherapies to the wayside.

By Kelly Bilodeau • Feb. 17, 2026

Ovid takes another big swing in neuroscience under a new CEO

After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.

By Meagan Parrish • Feb. 13, 2026

Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift

The pharma giant’s acquisition of in vivo CAR-T specialist Orna Therapeutics follows similar deals from AbbVie, Gilead, Bristol Myers Squibb and AstraZeneca.

By Michael Gibney • Feb. 12, 2026

A protein model designed for space could expand pharma’s definition of ‘druggability’

A computational biology company that started in space tech is looking to change how biopharma finds disease targets by modeling how proteins behave.

By Michael Gibney • Feb. 11, 2026

In a tough market, biotechs can be their own worst enemy

Even with sound science, startups can struggle to make their candidates go the distance.

By Alexandra Pecci • Feb. 10, 2026

New diagnostics define drug targets for Alzheimer’s, Parkinson’s and beyond

Emerging tests offer a bridge to pharma aiming to treat neurodegenerative diseases in their earlier stages.

By Kelly Bilodeau • Feb. 9, 2026

Investors crave safer, market-ready biotech bets, widening the early-stage funding gap

In these difficult financial times, venture capital dollars favor later-stage biotechs, forcing drugmakers with earlier-stage candidates to find alternative funding routes.

By Michael Gibney • Feb. 3, 2026